CKD-EPI Equation

Introduction

For nearly 50 years, the 1976 Cockcroft-Gault estimated creatinine clearance equation has been used to guide medication dosing for individuals with impaired kidney filtration function.

However, in recent years, the US National Kidney Foundation Workgroup and major US Pharmacy Organizations (AACP, ACCP, APhA, ASHP, HOPA) have supported transitioning to the 2021 CKD-EPI estimated glomerular filtration rate (eGFR) as the preferred equation for kidney function assessment in medication-related decisions.

The development of the Cockcroft-Gault equation inherently carries several limitations:

Development using data from a small cohort of 249 white males.
Use of an estimated - rather than scientifically quantified - 15% reduction for female patients.
Lack of validation in broader, more diverse patient populations.
Inconsistent application of body weight parameters and age adjustments due to highly variable criteria across clinicians and clinical practices.
Development prior to the standardization of serum creatinine assays.

The CKD-EPI formula adjusts for body surface area (BSA) and utilizes serum creatinine, age, and sex as variables.

In most patients with renal impairment, it provides a more accurate estimate of GFR.
Additionally, there is increasing availability and uptake of cystatin C for eGFR assessment.
In 2024, US FDA guidance for industry recommended using eGFR over the Cockcroft-Gault equation to evaluate kidney function in pharmacokinetic (PK) studies, leading to a rise in eGFR-based dosing recommendations.

A key point of contention during this transition is that historical renal dosage adjustments were established in units of ml/min.

Consequently, the standardized eGFR (ml/min/1.73m²) should be adjusted for the individual patient's BSA (eGFRBSAadj) when applied to medication dosing. This can be done by dividing the reported eGFR value by 1.73m² and multiplying by the patient's BSA, resulting in ml/min.
During this transition, exceptions may be warranted for ongoing clinical trials evaluating narrow therapeutic index medications, where trial protocols explicitly mandate an alternative method for GFR estimation.

While US guidelines promote implementation of the 2021 CKD-EPI equation, global consensus remains divided.

For instance, current UK NICE guidelines continue to recommend the 2009 CKD-EPI equation for eGFR estimation. NICE specifically advises using the 2009 CKD-EPI equation without an ethnicity adjustment factor, noting that the 2021 refit has not yet been sufficiently validated in UK populations.
Similarly, in Asian contexts such as Malaysia, clinical practice navigates a mix of international references. Neither the 2009 nor the 2021 CKD-EPI equations were developed using substantial Southeast Asian cohorts (specifically Malay, Malaysian Chinese, or Malaysian Indian populations). Consequently, while local laboratory systems routinely report eGFR (CKD-EPI) for kidney disease staging, replacing the Cockcroft-Gault equation with CKD-EPI for routine drug dosing - particularly for narrow therapeutic index medications - remains highly debatable.

Furthermore, fundamental limitations inherent to creatinine-based eGFR calculations persist across all equations:

Population Validation Gaps: A lack of regional or population-specific validation studies often causes international health authorities to hesitate before adopting updated equations like the 2021 CKD-EPI.
Extremes of Body Composition: Because creatinine is a muscle metabolite, eGFR values in patients at extremes of muscle mass must be interpreted with caution. Low muscle mass (e.g., severe sarcopenia or amputation) leads to an overestimation of actual GFR, whereas high muscle mass leads to an underestimation.
Non-Steady-State Conditions: eGFR equations assume stable serum creatinine levels over time. These models become mathematically invalid when serum creatinine changes rapidly, such as during Acute Kidney Injury (AKI) or in patients undergoing dialysis.

Universal consensus affirms that Glomerular Filtration Rate (GFR) remains the gold standard for assessing kidney function.

However, direct mGFR clearance measurements using exogenous filtration markers are costly, labour-intensive, and impractical for routine clinical care.